Key result
In Japanese community-dwelling women, the lowest tertile of serum sclerostin was associated with a higher risk of increased arterial stiffness compared to the highest tertile (OR 2.50; P=0.014).
Why the study?
Studies evaluating the relationship between serum sclerostin, a Wnt/β-catenin pathway inhibitor, and atherosclerosis have yielded inconsistent results.
Do lower serum sclerostin levels increase the risk of increased arterial stiffness in community-dwelling women aged ≥ 50 years?
Cohort (n=556)
Do lower serum sclerostin levels increase the risk of increased arterial stiffness in community-dwelling women aged ≥ 50 years?
Odds Ratio: 2.5
Absolute Event Rate: 22.2% vs 12.4%
p-value: p=.014
Suggests serum sclerostin may serve as a biomarker for arterial stiffness in postmenopausal women; leaves.
CONTEXT: Studies on the relationship between serum sclerostin, a Wnt/β-catenin pathway inhibitor, and atherosclerosis have yielded inconsistent results. OBJECTIVE: We aim to longitudinally investigate the relationship between serum sclerostin levels and the risk of increased arterial stiffness in Japanese community-dwelling women from the Japanese Population-based Osteoporosis Study (JPOS). METHODS: Of 1044 women aged ≥ 50 years whose brachial-ankle pulse wave velocity (baPWV) value was available in a baseline survey in 2011-2012, we excluded 374 whose baPWV values were ≥ 1800 cm/s, set as the cutoff for increased arterial stiffness, and 8 with missing data. Of the remaining 662 women, 556 participated in the 4- to 5-year follow-up study and were included in the analysis. The coefficient of variation of the sclerostin measurement was 3.45%. We obtained odds ratios (ORs) for sclerostin at baseline, categorized by tertiles, with the high tertile as reference for increased arterial stiffness. RESULTS: Increased arterial stiffness occurred in 94 women during a mean follow-up of 4.0 years. The increased arterial stiffness rates in the low, medium, and high tertiles were 22.2%, 16.1%, and 12.4%, respectively (trend test P = .013). The ORs for the medium and low tertiles for increased arterial stiffness were 1.58 (P = .205) and 2.16 (P = .027), respectively, after adjusting for age and baseline baPWV. After further adjustment for baseline body mass index, hypertension, hyperlipidemia, diabetes mellitus, estimated glomerular filtration rate, and whole-body bone mineral content, the ORs for the medium and low tertiles were 1.65 (P = .181) and 2.50 (P = .014), respectively. CONCLUSION: Lower serum sclerostin levels were associated with elevated risks for increased arterial stiffness in Japanese community-dwelling women.
No takes yet. Share an insight, caveat, or question.
Tamaki et al. (2024) conducted a cohort in Increased arterial stiffness (n=556). Low serum sclerostin levels (low tertile) vs. High serum sclerostin levels (high tertile) was evaluated on Increased arterial stiffness (baPWV ≥ 1800 cm/s) (OR 2.50, p=.014). In Japanese community-dwelling women, the lowest tertile of serum sclerostin was associated with a higher risk of increased arterial stiffness compared to the highest tertile (OR 2.50; P=0.014).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: